Pharmacological cognitive enhancement in schizophrenia

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations


Cognitive impairments in schizophrenia are common and severe. These impairments are also related to functional disability in schizophrenia. As a result, efforts are underway to enhance cognition in schizophrenia through a variety of pharmacological mechanisms. As part of this effort, a designated research design has been developed for this process, through an extensive consensus and validation effort. This paper reviews the methods for pharmacological cognitive enhancement, as well as previous results of efforts in the pharmacological domains. These domains include cholinergic, noradrenergic, serotonergic, glutamatergic, and GABA-ergic mechanisms. While previous results have not been particularly encouraging, there are many challenges that need to be overcome and many of the reasons for past failures may be due to resolvable issues. It is likely that this will be an area of research that will be developing extensively over the next decade and expanding to other conditions as well.

Original languageEnglish (US)
Pages (from-to)324-335
Number of pages12
JournalNeuropsychology Review
Issue number3
StatePublished - 2009
Externally publishedYes


  • Cognition
  • Psychopharmacology
  • Schizophrenia

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology


Dive into the research topics of 'Pharmacological cognitive enhancement in schizophrenia'. Together they form a unique fingerprint.

Cite this